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Abstract
Background Understanding the characteristics of 
smokers who are successful in quitting may help to in-
crease smoking cessation rates.
Purpose To examine heterogeneity in cessation out-
come at 6  months following smoking cessation behav-
ioral counseling with or without weight management 
counseling.
Methods 2,540 smokers were recruited from a large 
quitline provider and then randomized to receive pro-
active smoking cessation behavioral counseling without 
or with two versions of weight management counseling. 
A  Classification and Regression Tree (CART) analysis 
was conducted to identify the individual pretreatment 
and treatment characteristics of groups of smokers 
with different quitting success (as measured by point 
prevalence of self-reported smoking of any amount at 
6 months).
Results CART analysis identified 10 subgroups ranging 
from 25.5% to 70.2% abstinent. The splits in the CART 
tree involved: the total number of counseling and con-
trol calls received, whether a smoking cessation pharma-
cotherapy was used, and baseline measures of cigarettes 
per day, confidence in quitting, expectation that the 
study would help the participant quit smoking, the 
motivation to quit, exercise minutes per week, anxiety, 
and lack of interest or pleasure in doing things. Costs 
per quitter ranged from a low of $US270 to a high of 
$US630. Specific treatment recommendations are made 
for each group.
Conclusions These results indicate the presence of a sub-
stantial variation in abstinence following treatment, and 
that the total extent of contact via counseling calls of 
any type and baseline characteristics, rather than as-
signed treatment, were most important to subgroup 
membership and abstinence. Tailored treatments to sub-
groups who are at high risk for smoking following a quit 
attempt could increase successful smoking cessation.
Keywords  CART ∙ Smoking cessation ∙ Weight man-
agement ∙ Cost per quitter ∙ Intentions ∙ Abstinence ∙ 
Relapse
Introduction
Research shows that two-thirds of smokers calling 
quitlines are overweight or obese, and two-thirds are 
concerned that quitting smoking will cause them to gain 
weight [1]. Understanding how to optimize both smoking 
cessation and weight gain reduction in the quitline set-
ting is an important public health priority. Several pre-
vious studies have been conducted to determine the 
impact on tobacco abstinence and suppression of excess 
weight gain of adding weight management intervention 
to tobacco cessation counseling [2–4]. Those studies mo-
tivated the clinical study (the Best Quit Study or BQS) 
[5], providing data for this analysis. Here, we address the 
cessation outcomes of that study.
The BQS study tested the impact on abstinence and 
weight control of adding an evidence-based weight 
control intervention simultaneously with or sequen-
tially after cessation treatment delivered via telephone 
quitlines. Results of the randomized controlled trial 
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indicated that multiply imputed abstinence rates were 
lower for simultaneous (40.3%) than sequential (48.3%) 
and control (44.9%) participants at 6 months (p < .05) 
and 12 months (40.7% versus 46.3% and 46.0%, respect-
ively, p < .05). However, completers showed no differ-
ences in abstinence at 6 or 12  months. Observed and 
multiply imputed weight gain at 6 and 12  months was 
minimal and not different among treatment groups [5]. 
The treatments showed limited average weight manage-
ment effects, at least partly because individuals assigned 
to each treatment group differed substantially in their 
outcomes. The goal of the current paper is to identify 
characteristics of smokers who have low cessation rates 
at 6  months (the time period closest to the treatments 
received) and to compare their baseline and treatment 
characteristics with those who are successful at quitting. 
This can improve our understanding of predictors of 
the heterogeneity of quit outcomes and help identify 
groups who may need additional or different support 
with quitting.
Methods
Recruitment, Screening, and Randomization
The Best Quit intervention study is described in detail 
by Bush et al. [5–7] and summarized below. This study 
was implemented by Alere Wellbeing, a provider of to-
bacco quitline services and a phone/web-based weight 
management program. Participants were recruited from 
three state quitlines and 10 commercial (workplace) 
quitlines. Candidates were eligible if  they were 18 years 
of age and older, had a body mass index (BMI) ≥18.5, 
smoked at least 10 cigarettes per day (CPD), wanted to 
quit smoking within 30 days, and could speak and read 
English. A total of 2,528 individuals were found eligible 
and randomly allocated to one of three treatment groups 
(cessation alone, simultaneous weight management, or 
sequential weight management). Process and outcome 
data at 6 and 12 months were collected via web survey, 
phone, and mail.
Intervention and Control Arm Procedures
Smokers in all study arms received 10 coaching calls plus 
additional calls if  requested. Coaches made several at-
tempts per day over five different days to reach study par-
ticipants to complete each of their 10 planned counseling 
sessions. Treatment was participant focused, so the dur-
ation of each call varied by participant needs but followed 
the general protocol of 20 min for Call 1 and 10 min for 
remaining calls. The first “inbound” call was initiated by 
the smoker; “proactive” calls 2–10 were initiated by the 
coach. All participants could phone in to the quitline for 
additional support at any time. The cessation-only treat-
ment group (control) received five standard quitline ces-
sation calls followed by five healthy living program calls. 
The simultaneous group received five calls that combined 
cessation and weight management content followed by 
five healthy living program calls. The sequential group 
received five standard quitline cessation calls followed 
by five weight management calls. The healthy living calls 
acted as a contact control to equalize number of contacts 
with a coach across all three groups. For the simultaneous 
group, during the second call, a quitline coach completed 
the standard tobacco content and then transferred the 
participant to a registered dietician (RD).
Tobacco Cessation Treatment
The cessation treatment for all groups involved the Quit 
for Life (QFL) program that includes five telephone 
counseling sessions with a coach plus unlimited call-
ins to the quitline for help at any time, a website with 
support materials, a mailed Quit Kit, and free nicotine 
replacement therapy (NRT) in the form of patch, gum, 
and/or lozenge (0–8 weeks) depending on the contract 
for providing smoking cessation services and appropri-
ateness based on the participant’s medical condition.
Weight Management Treatment
The weight management program for the simultaneous and 
sequential treatment groups involved five counseling calls 
offered by coaches and RDs, mailed materials, and access 
to a web-based weight management program with on-line 
tracking forms, goal setting, and educational components. 
Coaches encouraged participants to set diet, physical activity, 
and weight goals, regularly self-monitor their weight, dietary 
intake (e.g., calories), stress, and physical activity level. The 
second call of the weight management intervention (Call 2 
for simultaneous, Call 8 for sequential) was delivered by an 
RD and covered calorie reduction strategies and the rationale 
for why and how to reduce caloric intake. Dietary, physical 
activity, and behavior change intervention content came from 
interventions proven to be efficacious in producing weight loss 
[8–11]. The physical activity component focused on moving 
more and sitting less. A stress reduction component focused 
on identifying and controlling stressful situations, finding and 
practicing coping skills, and monitoring progress.
Healthy Living Program Calls
The five healthy living (control) calls addressed sun pro-
tection, flu prevention, pedestrian safety, disaster pre-
paredness, and home energy savings. During these calls, 
coaches did not discuss tobacco or weight.
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Coaches
Interventions were delivered by experienced coaches 
and RDs. Coach training included reviewing the treat-
ment manual, listening to tape recorded “mock” calls 
and practicing the intervention content via role-plays. 
Coaches covered specific intervention topics visible to 
them via their on-line coaching application.
Data Collection
Participants’ demographic, smoking, and weight char-
acteristics were assessed by self-report surveys adminis-
tered at baseline by a quitline registration agent and a 
coach (depending on the item being assessed) and at 6 
and 12  months postrandomization by the survey team 
who were blinded to treatment arm. Participants could 
earn up to $110 for completing the three surveys ($30 for 
baseline; $35 for the 6 month survey, $35 for the 12 month 
survey, and $10 for early completion of the 12  month 
web survey). Two weeks prior to the 6 and 12  month 
target dates, participants were sent an email with a link 
to the survey. Survey nonresponders were sent reminder 
emails and those still nonresponsive were contacted by 
phone. Survey staff  attempted telephone outreach for at 
least 11 days and left several voice messages asking the 
participant to call the quitline. Individuals who still did 
not respond were sent a mailed copy of the survey with 
a stamped return envelope. Those who failed to return 
the mailed survey within 2 weeks were sent a short form 
survey asking only four questions (satisfaction, tobacco 
status, CPD, and current weight). The envelope stated 
that compensation was enclosed (a $2 bill was enclosed 
with the survey). In addition to self-reported data, call 
completion data were collected by Alere and included 
type and number of counseling calls completed (sched-
uled and participant-initiated calls).
Study Measures
Screening data collected by a registration agent when a 
smoker called into the quitline included standard demo-
graphic and tobacco use questions (e.g., name/address/
phone numbers, self-reported age, gender, and chronic 
disease status [asthma, pulmonary disease, heart disease, 
or diabetes) plus study-specific questions (CPD, height, 
weight, history of eating disorder, weight loss surgery, ac-
cess to internet; reachable for next 6 months; and willing 
to take additional five counseling calls). Baseline data 
collected by a coach prior to randomization included 
questions about race, ethnicity, education, marital status, 
depression/anxiety, whether dieting, level of concern 
about weight gains after quitting, and confidence about 
avoiding weight gain while staying quit. Content of the 
6  month and 12  month surveys included self-reported: 
duration of “no puff” abstinence, type and amount of 
tobacco used, cessation medications used, symptoms of 
depression or anxiety, satisfaction with the quitline, sat-
isfaction with the study, current weight, changes in diet, 
eating patterns, physical activity level, and use of an ac-
tivity monitor. A subset of these measures was used for 
the current paper.
The measures used for this paper are in line with the 
theoretical underpinnings of the study interventions and 
have been shown to be related to treatment outcomes. 
In accordance with the treatment model (social cogni-
tive theory) used for this study, treatment focused on 
personal, environmental, social, and behavioral factors, 
which influence each other in ways shown to change 
health behavior [12]. Within this theoretical model are 
concepts that have an effect on motivation and predict 
cessation and/or weight outcomes including: anticipated 
outcomes of a behavior (expectations) [4, 13] and confi-
dence in one’s ability to take action (self-efficacy) [12]. 
Specifically, we included variables known to predict 
health behaviors of tobacco cessation and /or weight 
control. These include personal factors such as lower 
age, lower education, and socio-economic status, being 
male, greater nicotine dependence measured by CPD, 
and weight-related factors (BMI, weight concerns, 
dieting behaviors). Motivation for quitting tobacco [14] 
and self-efficacy for smoking abstinence and confidence 
in avoiding weight gain are also predictive of health be-
havior changes [15–17].
Statistical Analysis
CART analysis was used to separate individuals into 
groups that exhibited different 6 month observed abstin-
ence. CART is a form of decision tree learning commonly 
used in data mining [18]. CART recursively splits parti-
cipants into subgroups based on a collection of variables 
that potentially predict the outcome of interest (which 
in this study is abstinence at 6 months). Predictors are 
selected based on their ability to optimally divide patients 
into smaller homogeneous subgroups, with each split 
improving homogeneity [19]. CART creates trees that are 
easy for clinicians to interpret [20, 21]. It is particularly 
useful in identifying subgroups of individuals because it: 
(a) does not assume that predictors are linearly related 
to the outcome of interest; (b) examines all possible cut-
points across all predictors at each split; (c) examines all 
possible interactions among predictors; and (d) is able 
to compensate for missing predictor values without the 
need for imputation [19, 21]. It has been widely used to 
identify subgroups of individuals who have positive or 
negative results from treatment [22–26]. Unlike most 
clustering approaches to identifying “hidden” subgroups 
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of the data, CART attempts to form subgroups that are 
homogeneous with respect to a particular target measure.
CART is a machine-learning method for constructing 
prediction models from data, which can be represented 
graphically as a tree [27]. In the current study, the end 
nodes are groups which have different 6  month ob-
served abstinence rates. The CART tree is obtained by 
recursively partitioning data by identifying a predictor 
of  6  month observed abstinence and by splitting the 
data on a value of  that predictor into “left” and “right” 
branches. Prediction error is measured in terms of  mis-
classification rate or cost (if  there are different costs 
associated with different types of  misclassification). In 
this study, CART was implemented using the R package 
RPART [28]. Receiver operating characteristic (ROC) 
analysis was used to calculate the ROC area under the 
curve (AUC) of  the groups. AUC is a measure of  the 
diagnostic ability of  a binary classifier as its discrim-
ination threshold is varied (where such variation al-
ters the sensitivity and specificity of  the classifier) [29]. 
AUC is a general method for assessing any binary clas-
sifier. The AUC was validated using fivefold cross valid-
ation. Cross validation involved randomly dividing the 
set of  respondents into five subsets, using one subset 
(containing 80% of all observations) to estimate the 
algorithm for determining end nodes and the comple-
mentary subset (of  20% of all observations) to assess 
the percentage correctly classified by those end nodes. 
This was repeated five times with the complementary 
subsets being nonoverlapping.
Table 1 displays the variables from the regression, 
baseline, and 6 month surveys and call completion data 
that were used in the CART analysis to predict observed 
30 day abstinence at 6 months, with the restriction that 
each end node contains 50 or more individuals. We 
chose 50 individuals because in our experience, smaller 
nodes are insufficiently stable and we wanted a large 
enough proportion of participants per node to justify 
the effort involved in formulating and implementing a 
tailored treatment. The 6 month variables reflected use 
of pharmacotherapies anytime from baseline and weight 
change from baseline to 6 months.
The predictive ability of the CART tree was assessed 
using three separate approaches. First, a logistic regres-
sion was performed where the dependent variable was 
abstinence at 6 months and the independent variable was 
a categorical variable denoting the different end nodes to 
establish that the groups were statistically significant pre-
dictors of abstinence. Second, a logistic regression [30] 
was conducted at each point at which a branch split to 
assess the statistical significance of that split. Third, the 
percentage of correct classifications and AUC [31] was 
calculated for all observations and using fivefold cross 
validation [32] to assess the extent to which the identi-
fied groups improved the assessment of abstinence. In 
addition, separate logistic or linear regressions were 
conducted for each of the predictor variable as the de-
pendent variable and a categorical variable denoting the 
end nodes as the independent variable to screen the pre-
dictors prior to examining them to determine whether 
there were potentially clinically important differences be-
tween the groups with respect to those predictors.
Cost Effectiveness Analysis
Cost per quitter was calculated for the purpose of 
determining groups where changes in treatment might 
lead to reduced costs by increasing the percentage 
quitting enough to compensate for the costs of add-
itional treatment. To determine the cost per quitter at 
6  months, the costs for various treatment components 
were estimated, excluding any costs that were only asso-
ciated with research activities. Labor costs for call min-
utes were calculated using an average wage of $27.84 per 
hour for a health educator (occupational code 21–1091 
in May 2016 from BLS.gov) to which was added 25% for 
benefits. Call attempts were costed at $1.53 each, letters 
sent at $0.49 each, voicemails at $3.06 each, QFL mater-
ials at $4.16 per enrollee, and Weight Talk materials at 
$8.67 per enrollee. Medications were costed at $18.79 per 
week of use, obtained by averaging costs from Costco, 
Walmart, and Amazon for 14 or 21 day NRT packages. 
We assumed the following: (a) 2 weeks of medication use 
for enrollees who were not part of an employer’s pro-
gram; (b) 4 weeks of medication use for enrollees who 
were part of an employer’s program with Optum and 
who stated that they had used medication and were not 
abstinent at 6 months; and (c) 8 weeks of medication use 
for enrollees who were part of an employer’s program 
with Optum and who stated that they had used medi-
cation and were abstinent at 6 months. The largest cost 
components were call attempts, call minutes, and medi-
cations, followed by voicemails. QFL materials, Weight 
Talk materials, and letters were relatively minor ex-
penses. While costs per enrollee were comparable across 
groups, costs per abstainer varied by a factor of more 
than 2 ($270 to $629 per abstainer).
Results
CART Tree
Figure 1 contains the CART tree for 30 day observed ab-
stinence at 6  months. The tree contains 10 end nodes, 
defined by various splitting variables such as quit con-
fidence. Each end node contains the following informa-
tion: (a) the number of observations in that end node, 
(b) the number of those observations that were either 
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Table 1 Variables used in CART analysis as predictors (independent variables)
Source Variable name, description, and coding
1 Registration Age (years), height (feet and inches), weight (lbs), BMI (calculated)
2 Registration Female (coded as 1 = Female, 0 = Other/Missing)
3 Registration Asthma, coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), diabetes (each coded as 
1 = Yes, 0 = No)
4 Registration NoChronic. None of 4 listed chronic conditions (coded as 1 = none of asthma, CAD, COPD or diabetes; 0 = at 
least one of asthma, CAD, COPD, and/or diabetes)
5 Registration CPD. Cigarettes per day (count)
6 Baseline Race (coded as 1 = White, 2 = Black or African American, 3 = Other)
7 Baseline Hispanic (1 = Yes, 0 = No)
8 Baseline Education (coded as 1 = <9th grade, 2 = 9–11, HS degree, 3 = some tech, tech/trade degree, 4 = some college, or 
5 = college degree)
9 Baseline Marital status (coded categorically as 1 = single, 2 = married or living together, 3 = separated, divorced, or widowed)
10 Baseline Anxiety. Over the last 2 weeks, how often have you been bothered by feeling nervous, anxious, or on edge? (coded 
as 0 = not at all, 1 = several days, 2 = more than half  the days, 3 = nearly every day) 
11 Baseline NoPleasure. Over the last 2 weeks, how often have you been bothered by little interest or pleasure in doing things? 
(coded as 0 = not at all, 1 = several days, 2 = more than half  the days, 3 = nearly every day)
12 Baseline Feeling down. Over the last 2 weeks, how often have you been bothered by feeling down, depressed or hopeless? 
(coded as 0 = not at all, 1 = several days, 2 = more than half  the days, 3 = nearly every day)
13 Baseline Worry. Over the last 2 weeks, how often have you been bothered by not being able to stop or control worrying? 
(coded as 0 = not at all, 1 = several days, 2 = more than half  the days, 3 = nearly every day)
14 Baseline ExerDays. Number of days of moderate to strenuous exercise in the last 7 days
15 Baseline ExerMins. Exercise minutes per day (On those days that you engaged in moderate to strenuous exercise, how 
many minutes, on average, did you exercise at this level?)
16 Baseline ExerTotMins. Calculated total number of exercise minutes per week. 
17 Baseline Dieting (coded as 1 = not currently dieting, 2 = dieting to lose weight, 3 = dieting to keep weight where it is right now)
18 Baseline Medicaid. Medicaid medical insurance (coded as 1 = Yes, 0 = No)
19 Baseline WgtGainLikelihood. How likely do you think it is that you will gain weight as a result of quitting/staying quit? 
(coded 1 = not at all likely, …, 10 = extremely likely)
20 Baseline Motiv. How motivated are you to quit? (coded 1 = low to 10 = high) 
21 Baseline QuitConf. How confident do you feel that you can quit? (coded 1 = not at all confident, …, 10 = extremely confident) 
22 Baseline WgtGainConf. How confident are you that you can avoid gaining weight while staying quit? (coded 1 = not at all 
confident, …, 10 = extremely confident)
23 Baseline WgtGainConc. Concern about gaining weight as a result of quitting (coded 1 = not at all, …, 10 = extremely 
concerned)
24 Baseline HelpQuit. Thinking about your study group, please rate the degree to which you feel the program will help you 
quit smoking. (1 = not at all likely, …, 10 = very high) 
25 6 month DrugCount. Number of pharmacotherapies used, selected from a list including NRT, nicotine gum, nicotine spray, etc. 
26 6 month M6_Wgt. Weight at 6 months (lbs) 
27 6 month M6_WgtGain. Weight change from baseline to 6 months (calculated)
28 Internal  
System
CommContract. Participant is covered by a commercial contract for smoking cessation services (coded 1 = Yes, 0 = No)
29 Calls TotTobCalls. Number of completed tobacco calls (count of any planned or ad hoc call that discussed tobacco, 
including calls that discussed both tobacco and weight in the simultaneous group)
30 Calls TotWgtCalls. Number of completed weight management calls (count of any planned or ad hoc call that discussed 
weight, including calls that discussed both tobacco and weight)
31 Calls TotTobWgtCalls. Number of completed calls that discussed both tobacco and weight management
32 Calls TotControlCalls. Number of completed healthy living calls
33 Calls TotCalls. Total number of completed calls. This measure included tobacco or weight calls initiated by the partici-
pant and healthy living calls. Calls that discussed both tobacco and weight were counted as two completed calls. 
34 Calls TotActiveCalls. Total number of completed calls excluding healthy living calls. 
35 Group Group. Randomization group (coded as 1 = control, 2 = sequential, or 3 = simultaneous)
NRT nicotine replacement therapy.
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abstinent or relapsed (excluding missing values), and (c) 
the fraction of nonmissing values for 30 day abstinence 
that were abstinent. Out of a total of 2,528 observations 
in the tree, 1,106 have values for 30 day abstinence. The 
tree also contains the names of the splitting variables. 
Ten groups of participants were identified and shown as 
Groups A–J. The values defining the splits, the expected 
direction for abstainers, and the p-values for each split 
are presented in Tables 2.
All of these splits were in the expected direction, with 
the exception of more exercise minutes per week being 
associated with lower abstinence. Closer examination of 
the two groups involved in the split on total exercise min-
utes suggests that the reason for this is that the group 
with fewer exercise minutes per week has a higher preva-
lence of chronic diseases and generally poorer health. 
This split differentiates Group D from E. Even though 
these two groups have equal stated high motivation to 
quit, the reasons behind that motivation differ (i.e., one 
motivated by poor health and the need to quit and the 
other by the desire for a healthy lifestyle) and this ap-
pears to result in different abstinence rates.
Statistical Significance
The logistic regression for the CART tree as a whole (i.e., 
where the dependent variable is 30 day observed abstin-
ence at 6 months and the independent variable is a cat-
egorical variable denoting the end nodes) was statistically 
significant at p < .001 (chi-squared [9]  =  134.3). The 
p-values for logistic regression at each split of the tree are 
shown in Table 2. They are all less than .05, and, with one 
exception, are all less than .004. To correct for multiple 
testing, we also calculated the false discovery rates [33] 
and found them all to be <0.05. The percentage classified 
correctly using the tree was 66.4% without cross validation 
and 61.5% with fivefold cross validation. Cross valid-
ation involved randomly dividing the set of respondents 
into five subsets, using one subset (containing 80% of all 
observations) to estimate the algorithm for determining 
end nodes and the complementary subset (of 20% of 
all observations) to assess the percentage correctly clas-
sified by those end nodes. This was repeated five times 
with the complementary subsets being nonoverlapping. 
The AUC without cross validation was 0.662 with a 95% 
confidence interval (CI) of 0.634 to 0.689. With cross val-
idation, the AUC was 0.615 with a 95% CI of 0.581 to 
0.648. Sensitivity (percentage correctly classified among 
nonabstainers) and specificity (percentage correctly clas-
sified among abstainers) were, respectively, 58.7% and 
73.6% without cross classification and 57.0% and 65.6% 
with cross validation.
Summary of Differences Between Groups by 
Characteristics
Tables 3 shows differences between groups on predictor 
variables passing a screen requiring a statistically sig-
nificant difference between groups. The table also con-
tains response rate and abstinence variables that were 
statistically significantly different between groups. 
Predictors, response, and abstinence variables are clus-
tered into logical groups, and for each variable, Tables 3 
also shows the average response across all respondents 
and (if  applicable) the odds ratio of  that variable with 
6 month observed abstinence. Values in the table that 
are in bold type face (italic type face) are sufficiently 
above (below) the average to be potentially clinically 
interesting. There was no difference between groups 









































A B C D E F G H I J
# Observations
# with 6m Abstinence
Pct Abstinent at 6m
Fig. 1. CART tree for 30 day observed abstinence at 6 months.
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Summary by Group
Below we summarize characteristics by group and spe-
cific tailored treatment recommendations:
Group A  had below average abstinence rates 
across all 6 and 12 month abstinence measures. Their 
distinguishing characteristics are low confidence that 
they can quit or avoid weight gain, low motivation 
to quit, low expectation that the BQS group will help 
them to quit, below average exercise, below average 
percentage Black, above average commercial con-
tract prevalence, and the highest cost per abstainer. 
Participants in this group may need treatment tailored 
to build their confidence in quitting, such as practicing 
quitting, celebrating successful mini-quits, and eliciting 
compelling reasons for quitting to increase their motiv-
ation. Encouraging these participants to increase their 
physical activity may help them overcome urges and 
symptoms of  nicotine withdrawal.
Group B had below average 30 day observed abstin-
ence rates but above average response rates, leading to 
average missing coded as relapser (MCR) abstinence 
rates. Their distinguishing characteristics are their lower 
than average prevalence and use of cessation pharmaco-
therapy at 6 months, racial makeup (higher percentage 
White and lower percentage Black), below average con-
fidence that they can quit or avoid weight gain, below 
average weight and BMI, and low commercial contract 
and Medicaid prevalence. This group had low cost per 
enrollee (due to lack of medication) but above average 
costs per abstainer (due to low abstinence rates). Tailored 
treatment around medication adherence and the im-
portance of using cessation medications and taking all 
coaching calls could help boost the quit rates in this 
group. This group may need more help identifying and 
addressing barriers to using NRT. Focusing on ways to 
increase confidence in quitting by experimenting with 
mini-quits and breaking the smoking cycle may help.
Group C had below average abstinence rates 
across all 6 and 12  month abstinence measures. Their 
distinguishing characteristics are above average use of 
cessation pharmacotherapy at 6 months, above average 
BMI, percentage female, percentage White, frequency 
of negative affect (worry, anxiety, lack of pleasure, and 
feeling down), Medicaid insurance, chronic obstructive 
pulmonary disease (COPD), presence of any of four 
chronic diseases, and below average percentage Black, 
confidence in ability to quit, commercial contract preva-
lence, and above average cost per abstainer. Members of 
this group may need more help to identify ways to in-
crease their confidence (see above).
Group D had average abstinence rates across all 6 
and 12 month abstinence measures. Their distinguishing 
characteristics are above average cessation pharmaco-
therapy prevalence and use, commercial contract preva-
lence, and exercise (days per week, minutes per day, and 
minutes per week) and below average age, percentage fe-
male, confidence that they can quit, frequency of nega-
tive affect (worry, anxiety, lack of pleasure, and feeling 
down), prevalence of Medicaid insurance, and preva-
lence of COPD or of any of four chronic conditions. 
This would appear to be a relatively physically and men-
tally healthy, young, and employed group. The costs per 
abstainer are about average. The quitline appears to be 
meeting the needs of this population.
Group E had above average 30 day observed abstin-
ence at 6 months but was about average on the other ab-
stinence measures. Their distinguishing characteristics 
were above average cessation pharmacotherapy preva-
lence and use and below average confidence in quitting 
or avoiding weight gain, negative affect measures (worry, 
anxiety, and lack of pleasure), and extremely low ex-
ercise (days per week, hours per day, and minutes per 
week). This may be a group with medical problems 
other than COPD, coronary artery disease, diabetes or 
asthma, which limit their exercise and result in generally 
Table 2 CART tree splitting information
Splitting variable Row with definition in Table 1 Values to left Values to right Expected direction for abstainers p-value *
QuitConf 21 <7.5 ≥7.5 Right <.001
HelpQuit 24 <6.5 ≥6.5 Right .001
DrugCount 25 <0.5 ≥0.5 Right .004
Anxiety 10 ≥2.5 <2.5 Right .001
ExerTotMins 16 ≥37.5 <37.5 Left .043
TotCalls 33 <6.5 ≥6.5 Right <.001
Motiv 20 <8.5 ≥8.5 Right <.001
CPD 5 ≥19.5 <19.5 Left .004
NoPleasure 11 ≥1.5 <1.5 Right .003
CPD cigarettes per day.
*The corresponding false discovery rate q-values are all less than 1% except for ExerTotMins, which is less than 5%.
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increased negative affect. Costs per abstainer were low. 
Providing a starter kit of pharmacotherapy appears to 
be helping participants to quit. Treatment recommenda-
tions include reinforcing the value of pharmacotherapy, 
encouraging continued use and providing suggestions 
for local sources of low-cost cessation medications. 
Discussing mini-quits or relapse prevention strategies 
may help boost participants’ confidence in quitting 
and staying quit. Encouraging participants to increase 
their physical activity may help with their confidence in 
quitting without weight gain and improve or alleviate 
anxiety and negative affect.
Group F had below average 30  day abstinence at 
6  months and below average 90  day abstinence at 
12  months. Their distinguishing characteristics were 
below average call completion and motivation to quit 
and above average weight, BMI, and confidence that they 
could quit. Costs per abstainer were average. Tailoring 
treatment around medication adherence and the import-
ance of taking all their counseling calls may be needed. 
Coaching on ways to boost their confidence and motiv-
ation could help members of this group.
Group G had below average 30  day observed and 
MCR abstinence at 6 months and below average MCR 
abstinence at 12  months. Their distinguishing charac-
teristics were below average response rate at 12 months 
(which would have been a contributing factor to their 
low MCR abstinence rates at 12 months), call comple-
tion, and commercial contract prevalence and above 
average confidence and motivation to quit, worry, anx-
iety, lack of  pleasure, frequency of  feeling down, CPD, 
COPD prevalence, and prevalence of  one or more of 
four chronic diseases. Costs per abstainer were above 
average due to large call minutes. Members of  this 
group may benefit from tailored coaching about their 
depressive symptoms in relation to smoking and nico-
tine withdrawal and the importance of  taking more 
coaching calls.
Group H had above average observed abstinence rates 
but below average 30 day MCR abstinence at 6 months 
(due to the low survey response rate at 12 months). Their 
distinguishing characteristics were below average call 
completion, low levels of worry, lack of pleasure, or fre-
quency of feeling down and above average confidence 
and motivation to quit, and CPD. Costs per abstainer 
were below average. Tailored treatment around the im-
portance of taking all counseling calls may be needed.
Group I  had above average 30  day observed abstin-
ence at 6  months. Their distinguishing characteristics 
were below average call completion, percentage White, 
and CPD and above average percentage Black, confi-
dence and motivation to quit, and confidence in avoiding 
weight gain. Costs per abstainer were below average. 
While the quitline appears to be meeting the needs of 
this group, encouraging individuals to take all calls could 
boost their quitting skills.
Group J had above average abstinence across all 
measures and times. Their distinguishing characteristics 
were below average percentage White and above average 
call completion, percentage in the control group, per-
centage Black, confidence in quitting, and prevalence of 
commercial contracts. Costs per abstainer were below 
average. The quitline appears to be meeting the needs of 
this group.
Discussion
We identified 10 distinctive groups from the CART 
tree analysis based on 30  day observed abstinence at 
6 months post intervention. Groups with low cessation 
rates had substantial differences from those with high 
cessation rates.
The majority of the variables that we examined as pre-
dictors either appeared in the CART tree or were statis-
tically significant predictors of groups in an analysis of 
Table 4 Average costs per enrollee and per abstainer
Cost component A B C D E F G H I J
Call attempts ($ per enrollee) 44.95 47.09 45.62 44.78 44.62 47.00 47.74 46.89 47.37 37.49
Letters ($ per enrollee) 0.22 0.24 0.25 0.19 0.20 0.29 0.28 0.28 0.28 0.04
Voicemails ($ per enrollee) 26.16 26.84 27.18 25.76 26.15 28.27 28.44 28.23 27.86 20.06
Call minutes ($ per enrollee) 44.09 46.34 41.89 46.61 45.28 31.15 31.06 31.45 32.78 79.29
QFL materials ($ per enrollee) 4.16 4.16 4.16 4.16 4.16 4.16 4.16 4.16 4.16 4.16
Weight Talk materials ($ per enrollee) 5.54 6.91 6.04 5.78 5.79 5.81 6.13 5.88 6.00 5.03
Medications ($ per enrollee) 49.78 0.00 54.16 71.35 71.71 44.23 42.04 54.40 58.39 63.91
Total costs ($ per enrollee) 174.90 131.58 179.30 198.63 197.91 160.91 159.85 171.29 176.84 209.98
Abstinent rate at 6 months (%) 27.8 25.5 30.4 43.5 63.6 35.4 30.5 57.2 65.6 70.2
Total costs ($ per 6 month abstainer) 629.14 516.00 589.80 456.62 311.18 454.55 524.10 299.46 269.57 299.12
QFL Quit for Life.
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variance. The only predictors that did not satisfy these 
criteria were Hispanic ethnicity, education, marital status, 
and whether the participants received weight manage-
ment counseling. While BMI at baseline and confidence 
in avoiding weight gain while staying quit were statis-
tically significant differentiators, other weight-related 
variables (amount of weight gain, self-assessed likeli-
hood that the participant will gain weight as a result of 
quitting, dieting, and concern about gaining weight as a 
result of quitting) were not. This relative lack of weight-
related variables (none of which are tree nodes) suggests 
that weight gain may be less important than other factors.
Study participants with low cessation rates (Groups 
A–C, F, and G) could be classified as having low con-
fidence in quitting; low outcome expectancies that the 
quitline will help them to quit smoking; low use of ces-
sation medications; more anxiety symptoms; and more 
physical activity. The group with low abstinence rates 
across all abstinence measures (Group A) was character-
ized by low confidence that they can quit or avoid weight 
gain, low motivation to quit, low expectation that the 
BQS group will help them to quit, below average exer-
cise, and were less likely to be Black. The group that had 
one of the lowest cessation rates (Group B) was charac-
terized by low confidence in quitting or avoiding weight 
gain similar to Group A, but this group also had low 
use of cessation medications, lower BMI, and a greater 
likelihood of being White. This group also had high 
rates of response to the 6 month survey and moderate 
engagement in counseling. Overall, smokers with low 
cessation rates may need more help boosting their con-
fidence in quitting, more cessation medications (or com-
bination pharmacotherapy such as nicotine patch plus 
gum or lozenge), and perhaps assistance with stress and 
anxiety. Tailored coaching around symptoms of nicotine 
withdrawal such as irritability and nervousness could be 
helpful.
Study participants with high 30  day cessation rates 
(Groups E, H–J) could be classified as having high confi-
dence in quitting and high motivation to quit, and these 
cessation rates are similar. Among these groups, Group J 
has a substantially higher 90 day cessation rate. Group J 
is also characterized by high use of cessation medication 
and high call completion. Of the participants with high 
cessation rates, this group was the only group who com-
pleted more than the average number of calls (tobacco, 
weight, control, and total). All other groups had lower 
than average calls across all call types. Therefore, while 
confidence in quitting and motivation to quit appear suf-
ficient to yield a high 30  day cessation rate, it appears 
that the addition of high use of cessation medication 
and treatment adherence (i.e., call completion) may be 
required to attain high 90 day abstinence.
In summary, confidence in being able to quit is an 
important variable, perhaps the most important. Why 
are some people more confident than others? Perhaps 
they have tried quitting many times before and have 
come close and now believe they can push a little 
harder and succeed. Perhaps they are optimists. What 
can be done to improve confidence? We also note 
that the splitting variable in Fig. 1 after QuitConf  is 
HelpQuit for individuals with lower confidence in their 
ability to quit and TotCalls for those with higher con-
fidence. Quitline assistance appears to make a differ-
ence for people with low confidence, but if  a person’s 
confidence is already high, she also needs adherence 
(as measured by more total calls). If  the person has 
high QuitConf  but is not fully following through 
(TotCalls <6.5), it seems that motivation really mat-
ters, so working on motivation with the quit coaches 
would presumably be helpful.
Limitations
Study participants were smokers who were ready to quit 
and called state or commercial quitlines for help. The 
study sample might not be representative of smokers 
who have not sought cessation treatment or those using 
other forms of cessation support. However, participants 
were similar to the quitline population and, like the gen-
eral quitline population, utilized only about half  of the 
standard five-call tobacco cessation calls offered. The 
CART groups might have been different with greater 
overall call completion. Participant burden related to the 
number of proactive calls for treatment and to complete 
lengthy follow-up surveys may have impacted willingness 
to enroll in the study.
The CART classification tree was developed only 
on those individuals who responded to the 6  month 
survey, but the tree was applied to all study participants 
to examine the characteristics of  the groups defined by 
the CART tree. Thus, there may be some differences 
between the group of  individuals used to generate the 
CART tree (all of  whom have values for abstinence at 
6 months) and the individuals used to characterize the 
end nodes (some of  whom do not have values for abstin-
ence at 6 months). We considered developing the CART 
tree based on 30 day MCR abstinence at 6 months, but 
that would have relied on the false assumption that 
anyone without a 6 month questionnaire was a relapser, 
and the tree would be partially attempting to predict 
response rate rather than abstinence. In addition, there 
was a delay in mailing the 6  month questionnaire to 
some respondents, which may be partially responsible 
for individuals who did not respond in time (i.e., by the 
ninth month). We also considered restricting all ana-
lyses just to individuals who responded to the 6 month 
survey, but they would not be representative of  the 
population, would eliminate our ability to calculate the 
response rate of  each group, and would have reduced 
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the sample size for calculating abstinence at 12 months 
because there were many participants who did not re-
spond at 6 months but did so at 12 months (as well as 
there being respondents at 6  months who did not re-
spond at 12 months).
Another limitation is that data on smoking and 
weight were self-reported without verification by direct 
objective measurement. Although biochemical validation 
of smoking is ideal, self-reported smoking is consistent 
with standard measures used telephone-based interven-
tions. Evidence suggests false reporting is minimal for 
low-intensity interventions with no face-to-face contact 
(the SRNT Subcommittee on Biochemical; An et  al.). 
Regarding the use of self-reported weight, the litera-
ture indicates that people tend to consistently under-
estimate their weight and their weight gain across time 
points, with underestimation disproportionately greater 
among the more overweight/obese [34]. To address these 
problems, we asked participants their current weight at 
baseline and follow-up and use these data to calculate 
the weight gain using their self-reported weights. Studies 
have shown strong correlations between measured and 
self-reported weight indicating that self-reported weight 
is an “excellent approximation of actual weight across 
a population” [34–36]. In addition, all participants used 
self-reporting, so any biases in reporting should affect all 
CART groups about equally.
Despite potential limitations, this study addresses 
an important public health issue and provides new 
data concerning the characteristics that distinguish in-
dividuals with successful abstinence at 6 months from 
those with unsuccessful abstinence. This study shows 
that adding weight control to cessation treatment may 
adversely impact short-term quit rates when delivered 
concurrently with tobacco treatment via a reduction in 
call completion. This trial contributes to the science of 
tobacco treatment by describing groups with differen-
tial 6  month quit rates among smokers seeking treat-
ment through a telephone tobacco quitline, two-thirds 
of  whom also received weight management counseling 
(either simultaneous with or sequentially after smoking 
cessation counseling), and demonstrates the import-
ance of  testing efficacious treatments in population 
based settings.
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